- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Rahway Today
By the People, for the People
EU Approves Keytruda Combo for Cervical Cancer Treatment
The new treatment regimen combines Keytruda, paclitaxel, and bevacizumab for adult patients.
Apr. 2, 2026 at 12:10pm
Got story updates? Submit your updates here. ›
The European Commission has approved the use of Merck's immunotherapy drug Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with persistent, recurrent or metastatic cervical cancer. This marks an important new treatment option for those battling this form of gynecological cancer.
Why it matters
Cervical cancer is the fourth most common cancer in women globally, with over 600,000 new cases and 340,000 deaths per year. The approval of this Keytruda-based combination therapy provides a new immunotherapy-powered treatment regimen that could significantly improve outcomes for many patients.
The details
The approval was based on data from the KEYNOTE-826 trial, which showed the Keytruda combination significantly improved overall survival and progression-free survival compared to chemotherapy alone. The treatment regimen is intended for adult patients whose cancer has returned after prior chemotherapy or who have metastatic disease that cannot be treated with surgery or radiation.
- The European Commission approved the new treatment on April 2, 2026.
The players
Keytruda
An immunotherapy drug developed by Merck that is used to treat various types of cancer.
Paclitaxel
A chemotherapy medication used to treat a number of different types of cancer.
Bevacizumab
A targeted cancer therapy that works by inhibiting the growth of new blood vessels that feed tumors.
What they’re saying
“This approval represents an important new treatment option for adult patients with persistent, recurrent or metastatic cervical cancer, a disease with high unmet medical need.”
— Dr. Scot Ebbinghaus, Vice President, Clinical Research, Merck Research Laboratories
What’s next
The new Keytruda combination regimen is expected to become available for eligible patients in Europe in the coming months, pending final pricing and reimbursement decisions in individual countries.
The takeaway
This approval of a Keytruda-based immunotherapy combination marks a significant advancement in the treatment of cervical cancer, providing a new option that could improve outcomes for many patients battling this challenging disease.
